Glenmark gets USFDA nod for generic skin ointment

The Mumbai-based firm's product is the generic version of Perrigo New York Inc's Desonide Ointment

Glenmark Pharmaceuticals today said it has received approval from the US health regulator to market Desonide Ointment, used to treat skin problems, in the American market.

Glenmark Pharmaceuticals Inc, a subsidiary of the company, has received final approval from the US Food and Drug Administration (US FDA) for Desonide ointment, the company said in a statement.

The Mumbai-based company's product is the generic version of Perrigo New York Inc's Desonide Ointment.

As per the latest IMS Health sales data, the product had annual sales of around USD 23.4 million.

Glenmark's current portfolio consists of 124 products authorised for distribution in the US marketplace and 62 ANDAs pending approval with the US FDA.

Shares of the company were at Rs 620 apiece at BSE, up 2.15 per cent from the previous close.